Podcasts about antibodies

Os avanços da ciência transformaram o tratamento dos cânceres hematológicos,ampliando as possibilidades terapêuticas e contribuindo para o aumento da sobrevida depacientes com doenças como o mieloma múltiplo. Ainda assim, diagnóstico, recaídas,acesso ao tratamento e qualidade de vida permanecem entre os desafios da jornada.¹ ⁴Neste episódio do podcast Notícia no Seu Tempo, a jornalista Carla Fiorio conversacom os hematologistas Walter Moisés Tobias Braga, médico responsável peloAmbulatório de Mieloma Múltiplo da Universidade Federal de São Paulo (SP 114081);e Deise Almeida (SP 149683), médica e diretora médica de Oncologia e Hematologia daGSK Brasil, sobre mieloma múltiplo e mielofibrose, duas doenças que fazem parte douniverso da onco-hematologia. A conversa aborda os avanços da medicina, asnecessidades que ainda não foram atendidas e as perspectivas para o futuro do cuidado. Este episódio é uma produção do Estadão Blue Studio com patrocínio da GSK.Referências para o texto de apresentação: 1. Nooka AK, Kastritis E, Dimopoulos MA. Treatment options for relapsed andrefractory multiple myeloma. Blood. 2015;125(20).2. Hungria V, et al. Emerging Real-World Treatment Patterns and ClinicalOutcomes of Multiple Myeloma in Argentina and Brazil: Insights from theTOTEMM Study in the Private Healthcare Sector. Curr Oncol. 2026;33:16.3. Eisfeld C, et al. Time trends in survival and causes of death in multiple myeloma.BMC Cancer. 2023.4. IQVIA Institute. Global Oncology Trends 2025.Referências para o episódio: 1. Nooka AK, Kastritis E, Dimopoulos MA. Treatment options for relapsed andrefractory multiple myeloma. Blood. 2015;125(20). REF-480872. CA: A Cancer Journal for Clinicians. Vol. 70. 2020. p. 7–30. REF-724913. Kazandjian D. Multiple myeloma epidemiology and survival: A uniquemalignancy. Semin Oncol. 2016;43(6):676–81. REF-2960414. Hungria, V.; Maiolino, A.; Pessoa de Magalhães, R.J., Filho; Pitombeira deLacerda, M.; Remaggi, G.; Scibona, P.; Seehaus, C.; Brulc, E.; Savoy, N.; Fantl,D.; et al. Emerging Real-World Treatment Patterns and Clinical Outcomes ofMultiple Myeloma in Argentina and Brazil: Insights from the TOTEMM Studyin the Private Healthcare Sector. Curr. Oncol. 2026, 33, 16.https://doi.org/10.3390/curroncol33010016. REF-316596 5. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5thedition of the World Health Organization Classification of HaematolymphoidTumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia.2022;36:1703–1719. doi:10.1038/s41375-022-01613-1 REF-2279396. Eisfeld C. et al. Time trends in survival and causes of death in multiplemyeloma. BMC Cancer. 2023. REF-3161117. IQVIA Institute. Global Oncology Trends 2025. REF-3191028. Observatório de Oncologia. Panorama do Mieloma Múltiplo no SUS [acesso emjul2026]. https://observatoriodeoncologia.com.br/estudos/cancer-de-sangue/mieloma-multiplo/2024/panorama-do-mieloma-multiplo/ REF-2963359. International Myeloma Foundation Latin America. Mieloma múltiplo: segundotipo de câncer sanguíneo mais frequente no mundo [Internet]. São Paulo: IMFLA; 2022 jun 07 [acesso em jul2026]. https://myeloma.org.br/mieloma-multiplo-segundo-tipo-de-cancer-sanguineo-mais-frequente-no-mundo/. REF-26981910. Kumar SK et al. Multiple Myeloma. Nature Reviews Disease Primers. 2017.REF-1817111. Yu B et al. BCMA-targeted immunotherapy for multiple myeloma. Journal ofHematology & Oncology. 2020. REF-10177912. Wang R et al. Antibody–Drug Conjugates (ADCs): current and futurebiopharmaceuticals. Journal of Hematology & Oncology. 2025. REF-28457113. Scherber RM, Mesa RA. Management of challenging myelofibrosis after JAKinhibitor failure. Blood Reviews. 2020. REF-16832614. Nicolosi M et al. Sex and degree of severity influence the prognostic impact ofanemia in primary myelofibrosis. Leukemia. 2018. REF-30724015. Mughal TI et al. Myelofibrosis-associated complications. International Journalof General Medicine. 2014. REF-16520816. Naymagon L, Mascarenhas J. Myelofibrosis-Related Anemia: Current andEmerging Therapeutic Strategies. Hemasphere. 2017. REF-16521017. OJJAARA® (momelotinibe). Bula do produto; Consulta Pública ANS sobreincorporação para mielofibrose. REF-32111518. Hungria, V; et al. Belantamab mafodotin plus bortezomib and dexamethasone inpatients with relapsed or refractory multiple myeloma (DREAMM-7): updatedoverall survival analysis from a global, randomised, open-label, phase 3 trial.Lancet Oncol 2025 Published Online July 15, 2025 https://doi.org/10.1016/S1470-2045(25)00330-4. REF-24715319. Mukhopadhyay, P., Abdullah, H.A., Opalinska, J.B. et al. The clinical journey ofbelantamab mafodotin in relapsed or refractory multiple myeloma: lessons indrug development. Blood Cancer J. 15, 15 (2025).https://doi.org/10.1038/s41408-025-01212-0. REF-24715320. ABBAS, A. K.; LICHTMAN, A. H.; PILLAI, S. Cellular and molecularimmunology. 10. ed. Philadelphia: Elsevier, 2022. REF-30571621. BIRGEGARD, G. et al. Inflammatory functional iron deficiency common inmyelofibrosis, contributes to anaemia and impairs quality of life. EuropeanJournal of Haematology, 2019; 102:235–240. REF-32205922. Al Noumani I; Expert Opinion on Pharmacotherapy; 2026; 27(8), 657–668.REF-331446 Material dirigido ao público geral. Por favor, consulte o seu médico. NP-BR-MMU-WCNT-260004/SETEMBRO DE 2026See omnystudio.com/listener for privacy information.

LIVE from ILADS: Tick Boot Camp reconnects with Nicole Bell, CEO of Galaxy Diagnostics, for a focused conversation about one of the biggest challenges in Lyme disease and tick-borne illness: getting an accurate diagnosis. Bell breaks down the differences between antibody testing, antigen testing, and PCR-based direct detection while explaining why stealth pathogens such as Borrelia, Bartonella, and Babesia can be so difficult to find. She also introduces Galaxy's BBB Direct Detect digital PCR testing, discusses emerging findings involving Babesia species, and explains why a negative antibody test doesn't always tell the entire story. For Bell, the mission is deeply personal. Her husband, Russ, initially tested negative for Lyme disease and was later diagnosed with Alzheimer's disease before his family ultimately discovered tick-borne infections were part of his complex illness. That experience helped redirect Bell's engineering and medical technology background toward improving diagnostics for other patients searching for answers. This interview was recorded live at the ILADS conference, so you may hear some of the energy and background activity of the event throughout the conversation. Why Can Lyme Disease Testing Be So Difficult? Bell begins by explaining one of the fundamental problems with diagnosing Lyme disease and other tick-borne infections: many of the pathogens clinicians are searching for can be difficult to detect. Some occur at low levels in the bloodstream. Others may migrate into tissues or circulate intermittently. Historically, much of tick-borne disease testing has therefore relied on indirect detection — looking for the patient's immune response rather than directly detecting the organism. Antibody testing can provide useful information, but Bell explains why interpretation can become complicated. A patient's antibody response can vary depending on factors including: Timing of infection Individual immune response Immune suppression or dysregulation Previous exposure Previous treatment Medications that suppress immune activity Cross-reactivity Whether an infection is current or historical This is why Bell views antibody testing as one tool rather than the entire diagnostic toolbox. Antibody Testing: Detecting the Immune Response Antibody testing is an indirect testing method. Instead of looking for Borrelia itself, for example, the test looks for evidence that the patient's immune system has responded to it. Bell discusses IgM and IgG antibodies and why timing matters. IgM antibodies are generally associated with an earlier immune response, while IgG responses can take longer to develop. In Lyme disease, that delay creates a particular challenge because early diagnosis and treatment can be especially important. Some infected patients may mount a strong measurable antibody response, while others may produce a weaker or delayed response. Bell points to research showing how dramatically immune responses can differ even under controlled experimental conditions. This creates an important distinction: A test of the immune response is not necessarily the same thing as a test for the pathogen itself. When Antibodies Don't Tell the Whole Story Bell uses her husband's experience to illustrate the stakes. Russ had likely been ill for years before his most significant symptoms emerged. By then, Bell says his immune system was dysregulated and his overall antibody levels were low. His Lyme testing was negative, and his worsening cognitive symptoms ultimately led to an Alzheimer's diagnosis. There is also another side to antibody testing. A person may have antibodies because of a previous infection even when the original infection is no longer active. That can make it difficult to determine whether persistent symptoms are associated with an ongoing infection, an undiagnosed coinfection, immune dysregulation, or another process. Bell's point is not that antibody testing has no value. It is that complex tick-borne illness may require more than one diagnostic tool. Antigen Testing: Looking for Evidence of the Pathogen The conversation then moves from indirect testing to direct detection. One method is antigen testing. Rather than measuring the immune system's response, an antigen test searches for a component associated with the pathogen itself. Bell discusses Galaxy's work with a urine-based Lyme disease antigen approach designed to capture and concentrate a protein shed by Borrelia. Why urine? Bell explains that Lyme-causing Borrelia may not remain abundantly present in the bloodstream. A pathogen-derived protein, however, may be filtered through the kidneys and become detectable in urine. Galaxy continues to work on direct-detection approaches to Lyme disease testing as it pursues broader clinical adoption and regulatory pathways. PCR Testing: Searching for Pathogen DNA Another form of direct detection is PCR testing. PCR looks for genetic material from the pathogen rather than relying on the patient's antibody response. Galaxy uses PCR-based approaches for pathogens including: Borrelia Bartonella Babesia But direct detection presents its own challenge. These organisms may occur at extremely low levels in a sample. A patient can be infected while very little pathogen DNA happens to be circulating in the particular blood sample collected that day. That is where digital PCR, or dPCR, becomes especially interesting. The Three B's: Borrelia, Bartonella & Babesia Bell introduces Galaxy's approach to what Tick Boot Camp often calls the Three B's: Borrelia. Bartonella. Babesia. As patient and clinician awareness of tick-borne illness has evolved, these three pathogens have become increasingly important to the conversation around complex cases. Galaxy's BBB Direct Detect digital PCR testing is designed to directly detect DNA from Borrelia, Bartonella, and Babesia. Unlike an antibody test asking whether the immune system has responded to a pathogen, direct PCR testing asks a different question: Can we find genetic evidence of the organism itself? How Digital PCR Searches for Low-Abundance Pathogens Bell gives a simple analogy for understanding digital PCR. Imagine searching for a needle in a haystack. Traditional PCR is trying to identify a tiny amount of pathogen DNA — the needle — among an enormous amount of human genetic material — the haystack. Digital PCR effectively divides that haystack into thousands of much smaller piles and examines them individually. That partitioning can make it easier to detect extremely small amounts of genetic material. Galaxy also uses a culture-enrichment step for Bartonella. The blood sample is placed in an environment designed to encourage Bartonella growth before PCR analysis, increasing the amount of target material available for detection. Learn more about Galaxy Diagnostics' direct-detection technology and its approaches to Borrelia, Bartonella, and Babesia testing. Why Are We Seeing So Many Coinfections? Tick Boot Camp and Bell also discuss an observation that has become increasingly common in patient interviews: many people with complex chronic tick-borne illness aren't reporting only Lyme disease. Instead, patients frequently describe combinations involving the Three B's and other infections. Why? Bell says several factors may contribute. Diagnostic technology has improved. Clinicians have become more aware of coinfections. Ecological research indicates ticks can carry multiple pathogens. But Bell raises another important possibility: patients carrying multiple pathogens may also be among those who become the sickest and therefore are disproportionately represented within chronic illness communities. That distinction matters. Observing many coinfections among severely ill patients doesn't necessarily mean every tick-borne disease patient has the same microbial picture. Bartonella, the Immune System & the Tipping Point Bell discusses Bartonella as an example of the complexity surrounding infection and illness. Exposure may be more common than many people realize, and Bartonella has multiple potential vectors and reservoirs. Bell describes a hypothesis in which some people may harbor an infection while their immune system keeps it under control. Then another infection, environmental exposure, significant stressor, or other immune-disrupting event may alter that balance. A person who had previously remained relatively healthy may cross what Bell describes as a tipping point and begin experiencing significant illness. This raises questions researchers are still working to answer. Were multiple infections transmitted simultaneously? Did they occur through separate exposures? Was one infection already present before another destabilized the immune system? Bell emphasizes that the answer may differ from patient to patient. Emerging Questions About Babesia Some of the most intriguing discussion in this interview involves Babesia. Bell explains that research associated with the North Carolina State University team has identified Babesia species in complex patients beyond the organisms traditionally emphasized in U.S. human babesiosis. She specifically discusses findings involving Babesia odocoilei and Babesia divergens-like organisms and contrasts those findings with expectations surrounding Babesia microti and Babesia duncani. Bell also discusses the possibility of low-level parasitemia — infections involving pathogen levels that may be much lower than the classic severe presentation clinicians associate with babesiosis. These emerging observations raise important research questions about Babesia species, their prevalence, their role in human disease, and whether existing diagnostic assumptions capture the full picture. Bell is careful in the interview to distinguish between what Galaxy's current assay detects and what researchers may suspect based on sequencing and related scientific work. Nicole Bell's Personal Mission Bell's work in tick-borne disease diagnostics grew out of an experience no family wants to have. Her husband, Russ, developed neurological and psychiatric symptoms, including cognitive problems, anxiety and hallucinations. Despite Bell specifically requesting Lyme disease testing early in his illness, his initial test was negative and his diagnostic journey eventually led to an Alzheimer's disease diagnosis. Bell later documented her family's experience in her memoir, What Lurks in the Woods. Today, she brings her engineering background and personal experience together in an effort to improve the diagnostic tools available to clinicians and patients. From MIT & Duke to Galaxy Diagnostics Nicole Bell is CEO of Galaxy Diagnostics and an engineer with extensive experience in medical devices and diagnostics. She earned bachelor's and master's degrees in Materials Science and Engineering from MIT and a master's degree in Biomedical Engineering from Duke University. Before joining Galaxy, she worked in technology and medical-device development, including leadership roles involving diagnostic platforms and FDA submissions. Bell became CEO of Galaxy Diagnostics in 2024, bringing together her professional background in engineering and diagnostics with the lessons learned through her husband's illness. The State of Lyme Disease Research Bell is also the primary author of The State of Lyme Disease Research in the United States for the Center for Lyme Action. The paper examines gaps in Lyme disease research and outlines recommendations involving fundamental science, diagnostics, prevention, treatment, and research infrastructure. In this interview, Bell references one particularly important issue explored in that work: delays in Lyme disease diagnosis and treatment are associated with a greater risk of patients experiencing persistent symptoms. Better testing isn't simply about producing a more sophisticated laboratory report. It's about helping clinicians get patients appropriate answers earlier. Key Topics in This Episode Lyme disease testing, Lyme diagnostics, Nicole Bell, Galaxy Diagnostics, Borrelia testing, Bartonella testing, Babesia testing, Three B's, BBB Direct Detect, digital PCR, dPCR, PCR testing, antibody testing, antigen testing, direct detection, indirect testing, stealth pathogens, Lyme disease antibodies, coinfections, polymicrobial tick-borne disease, low-abundance infections, Bartonella culture enrichment, Babesia microti, Babesia duncani, Babesia odocoilei, Babesia divergens, chronic Lyme disease, diagnostic delays, and tick-borne disease research. About This LIVE from ILADS Interview This short-form conversation was recorded in person at the 2025 International Lyme and Associated Diseases Society Annual Scientific Conference, From Terrain to Treatment: Advances in Vector-Borne Illness, held October 9–12, 2025, in San Antonio, Texas. Because these interviews were recorded live at the conference, they have a different feel from Tick Boot Camp's traditional long-form virtual and studio conversations — shorter, focused, and surrounded by the activity of one of the world's major gatherings of Lyme and tick-borne disease clinicians, researchers, advocates, and innovators. Explore all Tick Boot Camp LIVE from ILADS interviews. More from Tick Boot Camp Hear more conversations with Lyme disease doctors and healthcare professionals about testing, diagnosis, treatment, and complex tick-borne illness. Explore the Tick Boot Camp Podcast for interviews with patients, doctors, researchers, advocates, and innovators working to improve understanding of Lyme disease and help people move toward recovery.

When is a rash more than just a rash? And what should you be looking for before a patient even tells you something has changed? In our latest episode, cancer nurse practitioners Justin Hargreaves and Gillian Blanchard take a practical look at managing toxicities associated with antibody-drug conjugates, with a particular focus on PADCEV in urothelial cancer. From skin reactions and peripheral neuropathy to glucose changes and ocular symptoms, this episode explores what nurses need to be actively looking for, the questions we should be asking and why early recognition and escalation can make such a difference to patient safety and treatment continuity. This episode has been developed with support from Astellas and is available exclusively to CNSA members. This is a member only episde. To hear the full conversation, visit www.cnsa.org.au/podcast and log in using your CNSA membership details.

Normal TSH, still exhausted? Dr. Chris Motley explains the thyroid antibodies most people never get tested for, why a stomach infection called H. pylori keeps showing up alongside Hashimoto's, what a 2026 study found when it was treated, and what Chinese medicine has long said about digestion and a cold, tired body.  (00:00) Your antibodies are five times normal, and "nothing to treat yet"  (00:53) Welcome to the Ancient Health Podcast  (01:02) The most common thyroid disease, and the least recognized  (02:15) How your immune system attacks your thyroid: anti-TPO and anti-thyroglobulin  (02:55) What your thyroid does, and how TPO builds T3 and T4  (05:38) Why the antibodies start: Epstein-Barr, and one more pathogen  (06:13) H. pylori is not just a heartburn bug  (07:17) The stomach infection you forgot you had  (08:41) How people actually catch H. pylori  (10:16) A hidden infection and an over-alert immune system  (11:30) Mistaken identity: the molecular mimicry idea  (14:16) The Egypt study: treat H. pylori, watch TSH fall  (15:45) Why H. pylori belongs in every Hashimoto's workup  (16:47) A patient story: lifelong anxiety and a folder of labs  (23:16) Chinese medicine: Spleen and Kidney Yang deficiency  (24:56) The herbs Dr. Motley uses, and what the research shows  (27:40) That old infection could still be hanging around  (28:01) Normal labs, still feel crummy? What to ask for  (29:26) Share this with someone who needs it  (30:02) Disclaimer TSH alone can miss Hashimoto's. Over 90 percent of people with Hashimoto's carry TPO antibodies, and 50 to 80 percent carry thyroglobulin antibodies (StatPearls). Most standard panels check TSH only. Ask for both antibodies. The H. pylori and Hashimoto's link is real in pooled data, not in every study. A 15-study meta-analysis found about twice the odds of Hashimoto's with H. pylori infection (OR 2.16). One Italian study found the link only in Graves' disease. Molecular mimicry is a proposed explanation, not a proven one. 5. Treating H. pylori lowered TSH in levothyroxine-resistant women. TSH fell from 11.87 to 2.56 over four months in a 2026 Egyptian study. Antibodies moved much less. Levothyroxine needs stomach acid to absorb, so better absorption is the likeliest reason. What Doctor Motley Likes to Use:      Golden Thread: https://tinyurl.com/mvf6rftr Scutellaria Supreme (Chinese Scullcap): https://tinyurl.com/4murtnuk Want more of The Ancient Health Podcast? Subscribe to the YouTube channel. Follow Doctor Motley! Instagram Facebook Website *Do you have a ton more in-depth questions for Doctor Motley? Check out his course on emotions and the body in his membership. You'll find other courses full of his expertise and clinical wisdom, plus bring all your questions to his weekly lives! To try risk-free for 15 days click here https://www.doctormotley.com/15 Learn more about your ad choices. Visit megaphone.fm/adchoices

Cameron Turtle, CEO of Waltham, Mass.-based Spyre Therapeutics, on developing long-lasting antibodies for immune disorders.

Featuring an interview with Dr Douglas W Sborov, including the following topics: DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00) Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26) Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36) Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48) Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00) Prevention and management of ophthalmic events related to treatment with belamaf (21:27) Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49) Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27) Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53) CME information and select publications

Featuring a slide presentation and related discussion from Dr Douglas W Sborov, including the following topics: Overview of the treatment landscape for early relapsed multiple myeloma (MM) (0:00) Belantamab mafodotin (belamaf) mechanism of action and Phase II DREAMM-2 study of belamaf monotherapy in heavily pretreated MM (6:20) DREAMM-7 and DREAMM-8 Phase III trials of belamaf combination strategies in patients with MM in the second- and later-line settings (9:20) Monitoring for and management of belamaf-related ocular toxicities (12:29) Phase I DREAMM-9 trial of belamaf in combination with bortezomib/lenalidomide/dexamethasone (RVd) for transplant-ineligible newly diagnosed MM (16:23) Ongoing trials evaluating alternative belamaf dosing; practical considerations and recommendations for the administration of belamaf (19:07) CME information and select publications

It's New Tunesday: new releases from the past week! Give the bands a listen. If you like what you hear, support the bands! Today's episode features new releases by mind.in.a.box, Last Activity, All The Ashes, All Systems Out, Tevalik, Blokkontroll, Aesthetic Perfection, Antibody, Ministry, Boy Harsher, Graveyard Gossip, Das Kelzer, Cruc1fy, Ductape, The Spoiled, Dlina Volny, Mortal Boy, Adam Tristar, and Rosetta Stone!

Samuel Reich, Chief Executive Officer at SAB Bio, is developing a fully human antibody therapy designed to transform type 1 diabetes treatment by preserving patients' beta cells and their ability to produce insulin, rather than just managing symptoms with insulin and glucose monitoring. The drug is produced using the company's bovine platform which uses genetically modified cows to generate human immunoglobulins offering a safer more scalable alternative to rabbit-derived therapies. If successful, this approach could represent a functional cure, potentially transforming type 1 diabetes from a disease requiring daily insulin management to one requiring only periodic infusions. Samuel explains, "Our mission at SAB Bio is to transform what it means to get a type 1 diabetes diagnosis by changing the course of the disease, and not just treating the symptoms, with our new medicine, which is called SAB-142. Why type 1 diabetes? It's a major global unmet medical need that has largely been underserved in research until recently."  "Insulin and glucose monitoring are the standard of care, but they don't treat the disease. They don't treat the patient's illness. They just manage the symptoms and allow the patient to survive. So, they're essential, but they're not helping the patient be healthier or manage the disease process. Our mission is to treat the disease causing type 1 diabetes by saving the patient's beta cells and saving the patient's ability to make their own insulin. And exogenous insulin is no substitute for the patient's own ability to make insulin." "So we have a platform at SAB called the TcBovine, which is a transchromosomal bovine. And these are cows that are healthy and happy cows that look like normal dairy cows, but the cows make human IgG, or human antibodies, instead of cow IgG. And we vaccinate our cows with human thymocytes and purify the IgG from the cow plasma. And our drug is a fully human immunoglobulin, which targets human thymocytes. So, it does what the rabbit drug does, thymoglobulin, but it's human and can be given more safely without making the patient sick, and can be given for the life of the patient to continue to preserve their beta cells for the long term." #SABBio #Type1Diabetes #TD1 #JDRF#Immunology #ClinicalResearch #Endocrinology #AutoimmuneDisease #MedicalInnovation #BetaCells #T1D #HealthcareInnovation #ClinicalTrials sab.bio Download the transcript here

Samuel Reich, Chief Executive Officer at SAB Bio, is developing a fully human antibody therapy designed to transform type 1 diabetes treatment by preserving patients' beta cells and their ability to produce insulin, rather than just managing symptoms with insulin and glucose monitoring. The drug is produced using the company's bovine platform which uses genetically modified cows to generate human immunoglobulins offering a safer more scalable alternative to rabbit-derived therapies. If successful, this approach could represent a functional cure, potentially transforming type 1 diabetes from a disease requiring daily insulin management to one requiring only periodic infusions. Samuel explains, "Our mission at SAB Bio is to transform what it means to get a type 1 diabetes diagnosis by changing the course of the disease, and not just treating the symptoms, with our new medicine, which is called SAB-142. Why type 1 diabetes? It's a major global unmet medical need that has largely been underserved in research until recently."  "Insulin and glucose monitoring are the standard of care, but they don't treat the disease. They don't treat the patient's illness. They just manage the symptoms and allow the patient to survive. So, they're essential, but they're not helping the patient be healthier or manage the disease process. Our mission is to treat the disease causing type 1 diabetes by saving the patient's beta cells and saving the patient's ability to make their own insulin. And exogenous insulin is no substitute for the patient's own ability to make insulin." "So we have a platform at SAB called the TcBovine, which is a transchromosomal bovine. And these are cows that are healthy and happy cows that look like normal dairy cows, but the cows make human IgG, or human antibodies, instead of cow IgG. And we vaccinate our cows with human thymocytes and purify the IgG from the cow plasma. And our drug is a fully human immunoglobulin, which targets human thymocytes. So, it does what the rabbit drug does, thymoglobulin, but it's human and can be given more safely without making the patient sick, and can be given for the life of the patient to continue to preserve their beta cells for the long term." #SABBio #Type1Diabetes #TD1 #JDRF#Immunology #ClinicalResearch #Endocrinology #AutoimmuneDisease #MedicalInnovation #BetaCells #T1D #HealthcareInnovation #ClinicalTrials sab.bio  Listen to the podcast here

You can't forecast the next epidemic with precision, so why do we keep building preparedness plans that depend on guessing? Host Dennis Burton, Ph.D., sits down with Jim Crowe, Jr., M.D., professor and director of the Vaccine Center at Vanderbilt University, to map a more durable approach: AHEAD 100—Advanced Human Epidemic Antibody Defenses 100—an index-fund-style program to create and stockpile human monoclonal antibody drugs for the 100 infections most likely to spark major outbreaks. The goal is to take best-in-class neutralizing antibodies, move them beyond early clinical testing, and get them ready to deploy when the world needs them. They also honestly discuss scientific accountability, what the public is asking of researchers, and how to think about gain-of-function research without slogans.Links from this episode:The Scripps Research Institute Vanderbilt University Medical Center 

What if the test that diagnosed your Lyme disease, and the theory behind it, was never actually proven in the first place?In this episode of Integrative Lyme Solutions, Dr. K sits down with Dr. Thomas Cowan, a physician and author of The Contagion Myth, for a conversation that questions one of the most basic assumptions in the Lyme disease world: that borrelia has actually been shown to cause the illness. Dr. Cowan spent years as an ER doctor before turning his attention to what he calls the unexamined foundations of modern medicine, and in this conversation he walks through why he believes the original Lyme research, the antibody tests built on it, and even the concept of an immune system itself don't hold up to the kind of scrutiny any other medical claim would require.They get into the 1980s study that first linked spirochetes to Lyme disease, why Dr. Cowan says antibody tests can't be trusted to identify anything specific, and what he does instead when a patient walks in exhausted, in pain, and carrying a diagnosis that hasn't made them any better. If you've ever been told you have chronic Lyme disease and felt like the label explained less than it promised, this conversation offers a different way to think about what's actually happening in your body.Key Takeaways:Why Dr. Thomas Cowan argues the original Lyme disease study never proved borrelia causes the illnessThe case against Lyme antibody testing: why a positive IgG or IgM result may not mean what patients are told it meansWhy long-term antibiotic use, not lingering infection, may explain chronic Lyme disease symptoms for some patientsDr. Cowan's approach to chronic illness: treating a patient's health history instead of the Lyme disease labelWhy there is no clinical definition of Lyme disease, and what that means for anyone diagnosing themselves off a bullseye rash or brain fogSchedule a Free 15-Min Cancer/Lyme Consultation at The Karlfeldt Center: 208-338-8902Resources:The New Biology Clinic - https://newbiologyclinic.com/Medical Disclaimer: This content is for educational purposes only and is not intended to diagnose, treat, cure, or replace professional medical advice. Always consult your physician or qualified healthcare provider regarding any medical condition or treatment decisions.

Charlie and Zealeus talk about what gamers really want from: DRAGONCON Report from Zealeus The Buddy Movie that has Parents Up in Arms Voice Actor, Mike McFarland, Passes Away The Witcher TV Series will Follow Upcoming Game's Lead, Switch Lead Character Focus The Legend of Zelda: Ocarina of Time is Coming Out in November Steam May Have Leaked Quite a Few Upcoming Games Thanks to an Achievement List Leak Can the Re-release and/or remaster of games Be Seen as a Preservation of Culturally Significant Games? Spider-Noir Will NOT Get a Second Season The Rat Queens Board Game Gets New Life, and Love for Backers Who Got Previously Screwed Website: https://www.alteredconfusion.com Twitter: https://twitter.com/alteredconfusio Facebook: https://www.facebook.com/AlteredConfusion/ YouTube: https://www.youtube.com/AlteredConfusionLLC Instagram: https://www.instagram.com/alteredconfusion/ Patreon: https://www.patreon.com/AlteredConfusion Merch: https://www.alteredconfusion.tv/merch IndieCluster: https://indiecluster.com/ NoodleBoy Media: https://www.facebook.com/NoodleBoyMedia Hero Chiropractic: https://www.herochiropractic.com CrossPad Creative: crosspadcreative@gmail.com Agile Axiom: https://agileaxiom.com

“There isn't enough capacity for antibody-oligo conjugates out there today, full stop,” says Geoff Glass, CEO of Abzena. “And it's really because of the volume requirements for the diseases.”Geoff Glass is Chief Executive Officer of Abzena, the end-to-end, fully integrated CDMO and CRO for complex biologics and bioconjugates. He brings 30 years in life sciences, including at Patheon, Avadel, and Ncardia, and he chaired Abzena's board before taking the CEO seat last year. He's joined by Campbell Bunce, Abzena's Chief Scientific Officer, who runs discovery through GMP manufacturing across the company's San Diego, CA, Bristol, PA, and Cambridge, UK sites.Antibody-oligonucleotide conjugates (AOCs) have moved from concept to late-stage development in just a few years, attracting major investment along the way. In the latest PharmaSource podcast, Geoff and Campbell walk through where the modality came from, manufacturing considerations compared to ADCs, and the broader geopolitical and capacity challenges in the US.Read the full article.

TWiV explores how bacteriophages enable bet-hedge against bacterial immune defenses, and how transgenic mice engineered to produce human antibodies yielded potent anti-EBV candidates targeting gp350 and gp42, a promising step toward Epstein-Barr therapeutics. Hosts: Vincent Racaniello, Rich Condit, Brianne Barker, and Jolene Ramsey Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Dolly Parton, and advocate for science (Nature) Phage bet-hedging (Nat Micro) EBV monoclonal antibodies (Cell Rep Med) Letters read on TWiV 1353 Timestamps by Jolene Ramsey. Thanks! Picks of the Week Brianne – Did life on Earth emerge once or twice? Rich – Cassini Approaches Saturn (Wiki on Cassini) Jolene – Dolly Parton's rewrite of Jolene song for vaccines on CBS news (Youtube) Vincent – Thinking, Fast and Slow by Daniel Kahneman Listener Pick John – Dolly Parton Sings Vaccine, Vaccine Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

In this episode of Rheuminations, host Adam J. Brown, MD, untangles the confusing serologies of lupus by learning about their discoveries from the beginning. He answers questions like what's the deal with immunofluorescence patterns, why does SSA/SSB have two names (Ro/LA), and is double-stranded DNA antibody really attracted to both strands? ·       The story of antibodies in lupus. 3:27 ·       The "LE" factor. 10:11 ·       The changing fluorescent patterns of the staining of the nucleus/ENAs. 18:50 ·       The anti-Smith antibody. 24:51 ·       The mysteries of SSA and SSB. 28:52 ·       Double-stranded DNA. 36:32 ·       Crithidia luciliae. 40:30  We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. References: Aarden LA, et al. Ann NY Acad Sci. 1975;doi:10.1111/j.1749-6632.1975.tb29197.x Alspaugh MA, et al. Arthritis Rheum. 1976;doi:10.1002/art.1780190214 Aslpaugh MA, et al. J Clin Invest. 1975;doi:10.1172/JCI108007 Arana R, et al. J Clin Invest. 1967;doi:10.1172/JCI105677 Clark G, et al. J Immunol. 1969;PMED:4179557 Dubois EL, et al. Blood. 1957;doi:10.1182/blood.V12.7.657.657 Friou GJ, et al. J Immunol. 1958;doi:10.4049/jimmunol.80.4.324 Hargraves MM. Proc Staff Meet Mayo Clin. 1949;doi:10.1016/S0025-6196(25)08519-2 Haserick JR, et al. Am J Med Sci. 1950;doi:10.1097/00000441-195006000-00010 Rowell NR, et al. Arch Dermatol. 1963;doi:10.1001/archderm.1963.01590200064012 Tan EM, et al. J Clin Invest. 1966;doi:10.1172/JCI105479 Tsokos GC. J Immunol. 2006;doi:10.4049/jimmunol.176.3.1295

In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Joshua Hill and Jeffery Weitz on their latest articles published in Blood. Dr. Hill and Dr. Michaelis discuss the evolving landscape of infection risk in adults receiving bispecific antibody therapies for advanced B‑cell malignancies. They explore how these risks differ from those seen with allogeneic transplant, CAR T‑cell therapy, and traditional CD20‑directed antibodies, and touch on emerging approaches such as trispecific antibodies and evolving strategies for supportive care, including immunoglobulin replacement. In the second half of the episode, Dr. Michaelis is joined by Dr. Jeffrey Weitz to discuss new insights into the role of histidine‑rich glycoprotein in hemostasis. Their conversation delves into HRG's interactions with key platelet receptors, its behavior in inflammatory states like sepsis and COVID‑19, and how these observations may reshape thinking about thrombosis risk and future therapeutic approaches.Featured Articles: How I prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies | Joshua Hill, MDHistidine-rich glycoprotein modulates platelet adhesion and aggregation by binding to GPIbα and GPIIb/IIIa | Jeffery Weitz, MD

Program notes:0:38 Polymyalgia rheumatica treatment1:35 Antibody targets interleukin 17a2:35 Remission started at 12 weeks and was durable to 523:11 Cannabis and hyperemesis syndrome4:11 Cannabis-related ED visits5:11 Prior to the new coding didn't link6:05 Gene inhibition of PCSK-97:05 Encased in a nanoparticle8:11 Three vascular risk factors and dementia9:11 Stratified by age, sex, apoE status10:13 13 additional dementia-free years11:58 End

Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Manali Kamdar, Dr Tycel Phillips and Dr Jason Westin, moderated by Dr Abramson, including the following topics: Introduction (0:00) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (2:16) Bispecific Antibody Therapy for DLBCL — Dr Westin (27:21) CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Abramson (51:10) Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:13:24) Tolerability Considerations with CAR T-Cell Therapy and Bispecific Antibodies — Dr Brody (1:37:47) CME information and select publications

How have antibody trends changed over the decades? Janice Reichert, Ph.D., founder and editor-in-chief of mAbs, joins host Paul Carter, Ph.D., to discuss the evolution of monoclonal antibody therapeutics and their experiences with shaping—and documenting—the field. Their conversation covers the advances that have transformed the industry, evolving success rates for antibody therapeutics, and the growing sophistication of multispecific antibodies, antibody-drug conjugates, and more. Plus, they discuss both AI and China's emergence as major forces in antibody development. Links from this episode:  Genentech mAbs 

Labs read "normal" but you're gaining midsection weight, foggy and running at 70%? Your thyroid - not just perimenopause - may be the missing variable. Dr. Amie Hornaman explains why TSH alone misses the picture, how elevated reverse T3 "pools" and blocks T3 at the cell even when free T3 looks optimal, and why roughly 98% of women don't thrive on T4-only. She links falling progesterone, rising thyroid-binding globulin, low ferritin and the "thyropause" hitting 80-90% of women over 40. WHAT YOU'LL LEARN Why a "normal" TSH can completely miss a thyroid problem - and the five markers that actually reveal what's happening What reverse T3 "pooling" is, and how it blocks active thyroid hormone at the cell even when your free T3 looks optimal Why roughly 98% of women stop thriving on T4-only medication once they're past 40 How falling progesterone drives estrogen dominance, raises thyroid binding globulin, and quietly strands thyroid hormone before it reaches the cell What "thyropause" is, why it hits 80-90% of women over 40, and how it overlaps with the perimenopause symptoms you're blaming instead Why testosterone acts as armor against autoimmunity - and what its decline switches on How low ferritin, insulin resistance and cortisol compound thyroid-driven fatigue and stubborn belly fat TIMESTAMPS 00:00 - Intro: Why Midlife Women Go Undiagnosed & the Full Thyroid Panel Doctors Skip (TSH, Free T3/T4, Reverse T3, Antibodies)09:46 - Reverse T3 "Pooling," Why T4-Only Fails Most Women & What Actually Drives High Reverse T317:28 - How HRT, Progesterone Loss & Low Ferritin Hit Your Thyroid - Plus the "Thyropause" Switch22:09 - Core Thyroid Nutrients, Iodine Dosing Do's & Don'ts, and How to Actually Fix Low Iron40:14 - High Antibodies and Still Optimized? Hashimoto's Triggers & Protecting Your Thyroid45:40 - Midlife Belly Fat & Bloating: Root Causes, Smart Testing Order & the Gut-Healing Myth53:12 - Thyropause & Lean Athletes: Why Most Women Over 40 Get Hit - Plus The Thyroid Fix Book VALUABLE RESOURCES The Thyroid Fix (Dr. Amie's book) https://thyroidfixbook.com/ Dr. Amie Hornaman's website / book a call https://dramie.com/ Fixxr Supplements (Dr. Amie's line, incl. iodine) https://dramiehornaman.com/collections/supplements Follow Dr. Amie on Instagram https://www.instagram.com/dramiehornaman/ Thanks to my sponsor, Eight Sleep Sleep cooler, recover faster. The Eight Sleep Pod pre-cools your bed and adjusts all night for deeper sleep - dual-zone, so you and your partner each get your own temp.

Bispecific antibodies (BsAbs) continue to garner the interest of both academic and community cancer centers due to their rapid growth in FDA approvals and increasing use in hematologic malignancies and solid tumors. However, practical considerations such as treatment-related toxicities, choosing the right delivery model, and staffing constraints deter many programs from attempting to implement BsAbs. In this episode, CANCER BUZZ speaks with 2026 ACCC Innovator Award winner Kate Kennedy, MSN, APRN, ACNP-BC, AOCNP, an Outpatient Hematology Advanced Practice Provider (APP) Team Lead at Vanderbilt-Ingram Cancer Center, about her program's APP-led BsAb step-up dosing clinic. With APPs at the helm, this model enables efficient and specialty-expert management of therapies while optimizing physician resources. In addition, its adherence to step-up dosing protocols prioritizes patient safety and convenience while reducing inpatient resource utilization. "[It's important to look] at what you need to spend money on, [make] sure that you're spending money on the right things, and then [look] for areas like space and staff that maybe have capacity that you can utilize in a little bit of a different way to deliver this care." – Kathryn Kennedy, MSN, APRN, ACNP-BC, AOCNP Guest: Kathryn Kennedy, MSN, APRN, ACNP-BC, AOCNPOutpatient Hematology APP Team Lead Vanderbilt-Ingram Cancer Center Nashville, Tennessee Resources: ACCC 43rd National Oncology Conference 2026 ACCC Innovator Vanderbilt-Ingram Cancer Center Blog: An APP-Led Outpatient Bispecific Antibody Clinic Podcast: APPs Paving the Way in Leadership Blog: Maximizing the Role of APPs in Oncology Care Blog: Bispecific Antibodies Are Moving Forward; So Are the Implementation Questions  

On today's Good Day Health Show - ON DEMAND…Dr. Jack Stockwell, a NUCCA Chiropractor and GAPS Practitioner in SLC, UT (866.867.5070 | ForbiddenDoctor.com | JackStockwell.com), shares a holistic perspective on health news today. Dr. Jack offers an insightful discussion on recent developments in health policy and preventive medicine, including the value of comprehensive blood work, evolving COVID-19 vaccination recommendations, and the ongoing conversation surrounding cholesterol and heart health. Dr. Jack explains why looking beyond standard lab values can provide a more complete picture of overall wellness and explores concepts such as hybrid immunity, individualized healthcare, and informed decision-making. The episode also examines current discussions about vaccine safety, public health policy, and the importance of evaluating emerging research.Key Takeaways:Comprehensive blood testing can provide valuable insight into overall health beyond basic screening panels.Public health recommendations continue to evolve as new research becomes available.Individual health decisions are best made through informed discussions with qualified healthcare professionals.Cholesterol is one factor among many that contribute to cardiovascular health and should be evaluated within the broader context of overall risk.Staying informed and reviewing current scientific evidence can help individuals make thoughtful decisions about their health.For more on Good Day Health…Website: GoodDayHealthShow.comSocial Media: @GoodDayNetworks

As bispecific antibodies (BsAbs) become more integrated into oncology care, much of the focus has been placed on clinical protocols and operational readiness. However, less attention has been paid to the patient and caregiver experience. In this episode, CANCER BUZZ explores how it feels physically and emotionally for patients to begin and continue BsAb therapy. Grounded in real-world insights, this discussion highlights the logistical and emotional challenges that arise during the step-up period and early treatment phases and identifies opportunities for care teams to better support patients throughout their journey.  In partnership with HOPA and APSHO. This program was made possible with support from Johnson & Johnson and Genentech. Guest:  Leslie Mader, RN, BSN, OCN  Patient Care Coordinator, Bispecific Drug Therapy and IEC Therapy, Hematology/Stem Cell Transplant  Vanderbilt Ingram Cancer Center "It decreased the amount of time they had to be in the clinic, you know, because a lot of these people we're getting them back to their regular lives where they can work, they can go to you know continue on with life. So anything that we can give that's in an injection, and anything that's targeted to decrease systemic reactions is better for the patient."  - Leslie Mader "They think, oh, this is great. I'm going to get through it with no problems. And then they get dose three or dose four, and they're like crap. You know, they get discouraged. But usually, you know, we have emergency drugs that we give them dexamethasone, and it usually resolves quickly."  - Lesie Mader Resources: A Blueprint for Successful Integration of Bispecific Antibodies   Delivery Models for Administering T-Cell-Engaging Bispecific Antibodies  Delivering T-Cell-Engaging Bispecific Antibodies: Frequently Asked Questions (FAQ) ACCC Office Hours Recording - Bispecific Antibodies: One BiTE at a Time     Bispecific Antibodies Checklist for Community Providers Using Bispecific Antibodies in Community Practice: Challenge and Opportunities Expanding Access to Cellular and Bispecific Therapies: Considerations and Recommendations   

In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Stephen V. Liu, MD, the division chief of Hematology Oncology at MedStar Georgetown University Hospital, part of the MedStar Georgetown Cancer Institute, in Washington, DC.Their discussion centered on the continued evolution of precision medicine in non–small cell lung cancer (NSCLC), highlighting advances in molecular testing, targeted therapies, immunotherapy, and emerging treatment strategies presented at the 2026 ASCO Annual Meeting. Drs Park and Liu explored how lung cancer has become a model for precision oncology and emphasized that therapeutic advances across multiple tumor types have collectively shaped the current treatment landscape. They discussed the importance of understanding oncogenic drivers, overcoming resistance mechanisms, and moving effective therapies into earlier-stage disease to improve long-term patient outcomes.

Coeliac disease is often viewed as a straightforward gastrointestinal condition, but its presentation, diagnosis and long-term management can be far more complex than many clinicians appreciate.In this episode of the RCP Medicine Podcast Dr. Dushen Murugiah, Consultant Gastroenterologist and Trust Lead for Nutrition at Royal Surrey County Hospital NHS Foundation Trust, joins Dr Abhishek Ray to explore the modern approach to coeliac disease.Together they discuss classical and non-classical presentations, the challenges of diagnosing an often under-recognised condition, the role of serology and small bowel biopsy, and the importance of considering celiac disease in patients presenting with unexplained anaemia, nutritional deficiencies and other extraintestinal manifestations. The conversation also explores refractory celiac disease, practical challenges associated with lifelong gluten avoidance, and promising future therapies currently under investigation.This episode offers practical, evidence-informed insights for physicians, trainees and healthcare professionals involved in the assessment and management of patients with suspected or confirmed coeliac disease.  Explore our CPD portfolio by your career stageEducation and professional developmentLeadership CPDTeach the teacherEducational supervisorSix-step programme RCP Social MediaInstagramLinkedInFacebookBlueskyMusic Ep 50 onward - Bensound.com  Ep 1 - 49 'Impressive Deals' - Nicolai Heidlas Any adverts within this podcast may use computer generated voices

Jimmy Chang, Chairman and CEO of TaiMed Biologics,  is approaching critical unmet needs in HIV care, particularly for aging patients with comorbidities who face risks from drug-drug interactions with multiple medications. The company is advancing the next-generation antibodies designed for bimonthly injections and an alternative to daily oral medications, while minimizing enzymatic metabolism and associated drug interactions. While successful treatments for HIV have shifted the focus from survival to quality of life and managing a chronic condition, new challenges have emerged to ensure patient convenience and adherence.  Jimmy explains, "TaiMed is a biotech company based in Taiwan. Our focus is to develop innovative product for the HIV. And actually, over the years we have developed the first CD4-directed antibody for HIV treatment, and the product was approved in the US. And today we are currently focusing on developing the CD4-targeting antibody in a combination for long-acting HIV treatment."   "So in today's world, HIV therapies, HIV patients, or the people living with HIV, the field is HIV as a chronic disease. The patient can live longer and healthier just like everybody else. However, it requires dedication and commitment to medication because there's no cure today. HIV, the virus keeps mutating. So if the disease is not under control, this could be problematic, and basically one day the patient may run into a situation where most of the drugs do not work for the patient." "So in the earlier days, the innovations or the medications were mainly trying to have the virus under control, with the focus of the medications. And so nowadays, because people living with HIV actually have a very good health condition, just like typical individuals live longer and healthier. So this comorbidity, or we call it the polypharmacy drug-drug interaction, is really the challenge that the physicians or patients have to face every day. And with our innovations, we believe we have the opportunity to offer another innovative medication to specifically address those challenges." #TaiMed #HIVCare #LongActingTherapies #AntibodyTherapeutics #CD4 #Polypharmacy #InfectiousDiseases #TaiMedBiologics #EmpoweredPatient #HealthcareInnovation taimedbiologics.com Listen to the podcast here 

Jimmy Chang, Chairman and CEO of TaiMed Biologics,  is approaching critical unmet needs in HIV care, particularly for aging patients with comorbidities who face risks from drug-drug interactions with multiple medications. The company is advancing the next-generation antibodies designed for bimonthly injections and an alternative to daily oral medications, while minimizing enzymatic metabolism and associated drug interactions. While successful treatments for HIV have shifted the focus from survival to quality of life and managing a chronic condition, new challenges have emerged to ensure patient convenience and adherence.  Jimmy explains, "TaiMed is a biotech company based in Taiwan. Our focus is to develop innovative product for the HIV. And actually, over the years we have developed the first CD4-directed antibody for HIV treatment, and the product was approved in the US. And today we are currently focusing on developing the CD4-targeting antibody in a combination for long-acting HIV treatment."   "So in today's world, HIV therapies, HIV patients, or the people living with HIV, the field is HIV as a chronic disease. The patient can live longer and healthier just like everybody else. However, it requires dedication and commitment to medication because there's no cure today. HIV, the virus keeps mutating. So if the disease is not under control, this could be problematic, and basically one day the patient may run into a situation where most of the drugs do not work for the patient." "So in the earlier days, the innovations or the medications were mainly trying to have the virus under control, with the focus of the medications. And so nowadays, because people living with HIV actually have a very good health condition, just like typical individuals live longer and healthier. So this comorbidity, or we call it the polypharmacy drug-drug interaction, is really the challenge that the physicians or patients have to face every day. And with our innovations, we believe we have the opportunity to offer another innovative medication to specifically address those challenges." #TaiMed #HIVCare #LongActingTherapies #AntibodyTherapeutics #CD4 #Polypharmacy #InfectiousDiseases #TaiMedBiologics #EmpoweredPatient #HealthcareInnovation taimedbiologics.com Download the transcript here 

How can bispecific antibodies be safely delivered outside the hospital? Rahul Banerjee, MD and Ajay Nooka, MD discuss outpatient step-up dosing, prophylactic tocilizumab, CRS management, and practical tips for implementing bispecific therapy in academic and community practice.  

Welcome to Fertility & Sterility Roundtable, hosted by Dr. Emily Barnard and Dr. Ben Peipert! Each week, we will host a discussion with the authors of "Views and Reviews" and "Fertile Battle" articles published in a recent issue of Fertility & Sterility.  Today, we will be discussing the Views and Reviews from the May 2026 edition of Fertility and Sterility entitled "Male Infertility and Immune Function."  This Views and Reviews brought together experts, some of whom we will be interviewing today, who evaluated and summarized the evidence on how the immune system plays a role in male fertility and infertility in general. We know that infertility is caused, at least in part, by a male component in about 50% of cases, and we are appreciative to our guests for joining us in discussion today. We encourage all of our listeners to read the full articles in the journal as we will not be able to cover all the content in this episode. Dr. Michael L. Eisenberg is a Professor of Urology and Obstetrics & Gynecology at the Stanford University School of Medicine.  He is the director of Men's Health at Stanford.  Dr. Eisenberg's NIH-funded laboratory seeks to understand the association between a man's reproductive, sexual, and overall health.  Dr. Marcelo Mass Lindenbaum is a clinical research fellow at the Cleveland Clinic Foundation, soon to be transitioning to his urology residency at Cleveland Clinic Akron General. His primary academic research focuses on male infertility and its relationship with the urologic microbiome, and infection risks associated with prosthetic surgery. Dr. Scott Lundy is a Staff Urologist and Surgeon Scientist at the Cleveland Clinic Foundation who specializes in male reproductive medicine, sexual dysfunction, and microsurgery. Beyond his clinical practice, Dr. Lundy leads significant research efforts, including establishing a multi-institutional consortium to advance the study and treatment of male infertility. View Fertility and Sterility at https://www.fertstert.org/  

In this episode, Dr Sara Ann Scott and Dr Syeda Saba Kareem discuss toxicities and the safe management of bispecific antibodies used in the treatment of RRMM to improve outcomes for patients, including: The incidence of cytokine release syndrome (CRS), along with the grading system, treatment strategies, and the role of tocilizumab Neurologic toxicities like the clinical manifestation of ICANS and the ICE scoring system used to help assign grading and appropriate treatment with dexamethasone, levetiracetam, and/or high-dose methylprednisolone Infection susceptibilities associated with BCMA-targeted bispecific antibodies and how this varies for GPRC5D-directed targets throughout therapy How to set up and maintain a REMS program Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Syeda Saba Kareem, PharmD, BCOP Clinical Pharmacy Supervisor Malignant Hematology Moffitt Cancer Center Tampa, Florida Sara A. Scott, PharmD, BCOP Clinical Pharmacy Specialist,  Multiple Myeloma Emory Winship Cancer Institute Atlanta, Georgia Link to full program: https://bit.ly/3RUyrMx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On the latest episode of the Translating Proteomics podcast, Nautilus VP of Scientific Engagement and proteomics industry expert Sheri Wilcox joins hosts Parag Mallick and Andreas Huhmer for a thought-provoking discussion of their proteomics "hot takes.”Each “hot take” is a provocative opinion on a topic in proteomics. Specifically, they cover:Insufficient biological validation is one of the biggest problems in proteomics.Antibody validation remains a distributed, inconsistent, lab-by-lab responsibility, and this model for validation may not be sustainable going forward.AI cell models are overhyped.Check out the episode for deep explorations of each of these hot takes and their potential remedies.After listening, be sure to let us know whether you agree, disagree, or have your own hot take to share!

Highlights from the PER® CME activity "ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts William J. Gradishar, MD, FASCO, FACP; Rebecca Arend, MD, MSPH; Aaron Lisberg, MD; and Ulka Vaishampayan, MD, FASCO; discuss emerging antibody-drug conjugates and bispecific agents in lung, breast, endometrial, and prostate cancers, and how these agents may shift the therapeutic landscape in these disease.Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/adcs-and-bispecific-antibodies-across-solid-tumors-integrating-new-targets-new-data-and-new-decisions-xqkuThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from BioNTech.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

In this episode we speak with Alon Goren from UC San Diego about his work at the intersection of genomic technology development and chromatin biology. We discuss how his lab studies how the epigenome is regulated, how disruption of that regulation contributes to disease, and how technology can be improved to make results more robust and reproducible. We talk about his early interest in biology, how that developed through medical research training, and how a molecular biology lab shaped the direction of his career. He explains how curiosity about how cells and organisms work led him toward genomics and chromatin research. We then discuss several methods from his career, including early direct sequencing approaches for small amounts of DNA and RNA, ChIP-based methods for chromatin regulators, and work on improving ChIP-seq workflows. He explains why antibody choice matters, why monoclonal antibodies can improve reproducibility, and how automation helped scale the process. We also cover his work on spike-in normalization, including the risks of using exogenous chromatin incorrectly and the need for better safeguards in genome-wide comparisons. He describes a newer approach that uses two spike-ins to provide multiple checks on normalization. Finally, we discuss his work on short tandem repeats, zebrafish heart regeneration, and SIRT6-related polymerase pausing, as well as a newer platform that converts molecular interactions into sequencing-readable barcodes. He closes by stressing the importance of validation, careful protocol design, and methods that can be used reliably by multiple people. References Ram, O., Goren, A., Amit, I., Shoresh, N., Yosef, N., Ernst, J., Kellis, M., Gymrek, M., Issner, R., Coyne, M., Durham, T., Zhang, X., Donaghey, J., Epstein, C. B., Regev, A., & Bernstein, B. E. (2011). Combinatorial patterning of chromatin regulators uncovered by genome-wide location analysis in human cells. Cell, 147(7), 1628–1639. https://doi.org/10.1016/j.cell.2011.09.057 Busby, M., Xue, C., Li, C., Farjoun, Y., Gienger, E., Yofe, I., Gladden, A., Epstein, C. B., Cornett, E. M., Rothbart, S. B., Nusbaum, C., & Goren, A. (2016). Systematic comparison of monoclonal versus polyclonal antibodies for mapping histone modifications by ChIP-seq. Epigenetics & chromatin, 9, 49. https://doi.org/10.1186/s13072-016-0100-6 Patel, L. A., Cao, Y., Mendenhall, E. M., Benner, C., & Goren, A. (2024). The Wild West of spike-in normalization. Nature biotechnology, 42(9), 1343–1349. https://doi.org/10.1038/s41587-024-02377-y Ben-Yair, R., Butty, V. L., Busby, M., Qiu, Y., Levine, S. S., Goren, A., Boyer, L. A., Burns, C. G., & Burns, C. E. (2019). H3K27me3-mediated silencing of structural genes is required for zebrafish heart regeneration. Development (Cambridge, England), 146(19), dev178632. https://doi.org/10.1242/dev.178632 Patel, L., Cao, Y., Xu, T., Modolo, E., Dishon, T., Zhang, L., Mendenhall, E., Heinz, S., Simon, I., Benner, C., & Goren, A. (2025). Improved spike-in normalization clarifies the relationship between active histone modifications and transcription. Genomics. https://doi.org/10.1101/2025.11.25.690627 Xu, T., Wang, J., Shin, Y., Cao, Y., Zhang, L., Modolo, E., Dishon, T., Fisher, J., Norton, M., Fry, C. J., Farjoun, Y., Mendenhall, E., Heinz, S., Benner, C., & Goren, A. (2026). Multiplexed measurements of protein-protein interactions and protein abundance across cellular conditions using Prod&PQ-seq. Genomics. https://doi.org/10.64898/2026.01.01.697286 Related Episodes Taking ChIP from Yeast to ENCODE to Enable Genome-Wide Regulatory Protein Mapping (Peggy Farnham) Comparing CUT&Tag to ENCODE ChIP-Seq in Alzheimer's Disease Samples (Sarah Marzi) Chromatin Profiling: From ChIP to CUT&RUN, CUT&Tag and CUTAC (Steven Henikoff) Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HCN865. CME/MOC/AAPA credit will be available until July 1, 2027.Scaling New Heights in Lung and Breast Cancer Care: Harnessing the Power of Antibody–Drug Conjugates in Patients With Brain Metastases In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HCN865. CME/MOC/AAPA credit will be available until July 1, 2027.Scaling New Heights in Lung and Breast Cancer Care: Harnessing the Power of Antibody–Drug Conjugates in Patients With Brain Metastases In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HCN865. CME/MOC/AAPA credit will be available until July 1, 2027.Scaling New Heights in Lung and Breast Cancer Care: Harnessing the Power of Antibody–Drug Conjugates in Patients With Brain Metastases In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HCN865. CME/MOC/AAPA credit will be available until July 1, 2027.Scaling New Heights in Lung and Breast Cancer Care: Harnessing the Power of Antibody–Drug Conjugates in Patients With Brain Metastases In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HCN865. CME/MOC/AAPA credit will be available until July 1, 2027.Scaling New Heights in Lung and Breast Cancer Care: Harnessing the Power of Antibody–Drug Conjugates in Patients With Brain Metastases In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

We would love to hear from you! Please send us your comments here. --------Thank you for listening! Your support of Joni and Friends helps make this show possible. Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org. Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

Current Lyme disease tests look for antibodies produced by the immune system in response to Borrelia burgdorferi bacteria transmitted to humans by infected blacklegged ticks. My guest today says, "The problem is that these antibodies don't have the right characteristics to be clinically useful". New research led by Tufts University School of Medicine suggests that a group of immune molecules called anti-lipid antibodies may address these shortcomings. Joining me today do discuss this problem and the potential solution is Peter Gwynne, Phd. Dr Gwynne is a research assistant professor at Tufts University School of Medicine and the senior author of the new paper published in the journal, Infection and Immunity.   Antiphospholipid antibodies in acute and post-treatment Lyme disease

You asked your doctor for help. You got your blood work. You were told everything is normal. And you walked out feeling more confused than when you walked in, because if nothing is wrong, why do you still feel terrible? In this episode, I'm walking you through every lab I use to uncover weight loss resistance, what I'm looking for on each one, and why your doctor and I can look at the exact same numbers and come to completely different conclusions.IN THIS EPISODE, YOU'LL LEARN:Why "your labs are normal" doesn't mean your body is functioning optimally, and the real difference between diagnosable and suboptimalWhy cutting calories below 1,500 when you're already weight loss resistant creates a brand new problem instead of a solutionWhat the DUTCH test shows us that a standard blood draw simply can't: what you're producing, how you're using it, and how you're detoxing itWhy the GI MAP is my favorite test of all, and why your gut is usually the environment your hormones are responding toThe energy conversion markers most women never get checked: vitamin D, a full iron panel, and B12Why a TSH alone is not a thyroid panel, and the five markers I want to see insteadThe blood sugar trio (fasting insulin, fasting glucose, hemoglobin A1C) and why fasting insulin is the one that tells the truthWhat an abnormal lipid panel in midlife is really telling you (hint: it's almost never your red meat)Why I don't put much weight on a normal CRP when your symptoms are telling a different storyTIMESTAMPS: 01:15 Welcome to Part 3: Getting the Data 02:05 Why Your Doctor Says "Normal" and I Say "Suboptimal" 04:17 When Eating Less Stops Working (And Starts Causing Harm) 06:34 Labs End the Guesswork Spiral 08:55 Data + Belief: Why Women Shift Fast When They Can See the Why 09:45 The DUTCH Test: Hormones, Cortisol Rhythm, and Detox Pathways 13:11 The GI MAP: Gut Lining, Digestive Capacity, and the Real Story on Pathogens 15:30 Vitamin D: The Hormone Pretending to Be a Vitamin 17:41 The Full Iron Panel: Your Energy Conversion Marker 19:37 Vitamin B12 and the Gut Absorption Connection 20:40 The Full Thyroid Panel: TSH, Free T4, Free T3, Reverse T3, and Antibodies 24:22 Fasting Insulin, Fasting Glucose, and Hemoglobin A1C 26:42 The Lipid Panel: It's Blood Sugar and Muscle, Not Your Eggs 27:50 CBC, CMP, and CRP: The Foundation Check 29:05 How the Midsummer Reset Targets Low-Grade Inflammation 30:51 You're Not Crazy, Lazy, or Lacking Discipline. This Is Data.RESOURCES:

Featuring perspectives from Prof Giuseppe Curigliano, Prof Rebecca A Dent, Dr Erika Hamilton, Prof Nadia Harbeck and Dr Hope S Rugo, moderated by Dr Rugo, including the following topics: Introduction (00:00) Evolving Role of Antibody-Drug Conjugates (ADCs) in the Management of Metastatic Triple-Negative Breast Cancer — Prof Dent (02:57) Integrating ADCs into the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano (29:01) Role of ADCs in the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Rugo (52:36) Emerging Utility of ADCs for Localized Breast Cancer — Prof Harbeck (01:14:36) Tolerability Considerations with ADCs for Breast Cancer — Dr Hamilton (01:38:10) CME information and select publications

Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs) (2:07) Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23) Currently Available ADCs for Gynecologic Cancer Management (26:37) Currently Available ADCs for Lung Cancer Management (44:07) Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55) Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07) Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01) NCPD information and select publications  

This week on Tiny Show and Tell Us, a listener introduces us to "FARTs" — a silly acronym for galactic gas outflows — and sends us down a rabbit hole of dying stars and recycled cosmic gas in the early universe. Then we discuss the decades-long search for broadly neutralizing antibodies (bNAbs) that can target many HIV strains at once. One bNAb that looks promising is in clinical trials right now! We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

JHLT: The Podcast returns for July with a paper entitled "Comparing DSA-negative and DSA-positive antibody-mediated rejection in heart transplants: Results from the Trifecta-Heart study," available online now and in the July print issue of JHLT. Today's guests are first author Katelynn S. Madill-Thomsen, PhD and senior author Philip F. Halloran, MD, PhD, both from the Alberta Transplant Applied Genomics Center in Canada. In the episode, the authors and editors discuss: Striking similarities—and key differences—in the DSA-negative and DSA-positive groups Changes to clinical practice based on the findings, including innovations from the kidney transplant community Future studies, including tools and therapies that could be explored for improved clinical outcomes For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Bringing home a new baby comes with so many questions, and feeding is often at the top of the list. In this solo episode, Dr. Carole Keim walks parents through the basics of newborn feeding with a reassuring message: fed is best. She explains what to expect during the first days of life, including how small a newborn's stomach really is, how breastfeeding develops over time, and why feeding can feel challenging in the beginning. Parents will learn about colostrum, milk production, feeding frequency, and how to recognize signs that their baby is getting enough to eat.  Dr. Keim also explores common breastfeeding challenges, practical tips for improving latch and milk supply, and the role of pumping, bottle feeding, donor milk, and formula. She discusses the benefits of breastfeeding while also emphasizing that there are many safe and healthy ways to nourish a baby. Whether you plan to breastfeed, formula feed, pump, or combine methods, this episode offers evidence-based guidance and encouragement to help you make feeding decisions with confidence during those important first weeks with your newborn.  Key Moments 00:00 Welcome and why “Fed is Best” matters 01:18 Why breastfeeding can be harder than expected 02:43 Newborn stomach size and feeding volumes by day 03:56 The first nights of feeding and newborn hunger patterns 05:03 Pumping, storing colostrum, and building milk supply 06:19 Benefits of breastfeeding for moms and babies 10:33 Breastfeeding recommendations and realistic feeding choices 14:35 Latch basics and breastfeeding troubleshooting 18:37 Pacifiers, nipple care, and knowing if baby is getting enough 22:41 Tongue ties, milk supply tips, and common breastfeeding concerns 31:36 Bottle feeding, formula options, and choosing the right formula 39:21 Final encouragement: nourishing your baby with confidence __ Why Breastfeeding Matters  Benefits for Baby Nutrition tailored to infant needs Antibodies and immune protection Lower risk of ear infections, diarrhea, and some respiratory illnesses Lower risk of SIDS Possible long-term reduction in obesity and diabetes risk Benefits for Parent Uterine recovery after birth Reduced postpartum bleeding Convenience and lower cost Possible reduction in breast and ovarian cancer risk Positioning and Latch Basics  Good Positioning Baby's ear, shoulder, and hip aligned Baby brought to breast, not breast to baby Nose to nipple alignment Signs of a Good Latch Wide-open mouth Lips flanged outward Deep latch, not shallow nipple sucking Rhythmic suck/swallow pattern Signs of Poor Latch Significant pain Clicking Cracked nipples Baby still hungry after long feeds How to Know Baby Is Getting Enough Milk Signs Wet diapers and stools Weight trends Swallowing sounds Baby seeming satisfied after many feeds Typical Expectations Initial weight loss can be normal Pediatric follow-up is important in the first days after discharge Red Flags Poor urine output Lethargy Persistent jaundice Dehydration signs When to Seek Help  Lactation Support Lactation consultants Pediatricians Family physicians Midwives Postpartum nurses Urgent Reasons to Seek Care Baby not waking to feed Fever Signs of dehydration Severe maternal breast pain/redness/fever Poor weight gain Giving bottles of formula How to choose regular, preemie, soy, anti-reflux, sensitive, hydrolyzed, goat, organic How to mix Follow the instructions on package closely Do NOT make your own infant formula; use one that is commercially available Mix with clean water; doesn't need to be distilled or boiled Any temp is ok; aim for cool to room temperature when you feed baby  Can mix up to 1 day worth at a time in the fridge Used bottles need to be finished within 2 hours or thrown away; can't be put back in the fridge Check out The Baby Manual on Amazon.  It will give you peace of mind when your new baby arrives.   __  Resources discussed in this episode: The Holistic Mamas Handbook is available on Amazon The Baby Manual is also available on Amazon __ Contact Dr. Carole Keim MD Website: CaroleKeim.com Linktree TikTok Instagram ---FullScript VitaminsUse this link to get 10% off and free shipping for orders over $50.HIRO DiapersUse code DRCAROLEKEIM for a discount at checkout. Click here. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

“Narrative remains a pretty unbeatable delivery device for information.” — Patrick Radden Keefe Has London really fallen? That's the question Patrick Radden Keefe — staff writer at The New Yorker and bestselling author of Empire of Pain and Say Nothing — addressed in his new book, London Falling: A Mysterious Death in a Gilded City and a Family's Search for Truth. One thing for sure is that Keefe himself hasn't fallen. He's been surprised by the book's success. “I thought the antibodies would get up because I'm an interloper,” the American confesses about writing about Britain. Antibodies or not, the book has been a #1 bestseller in both the UK and US. And we can look forward to an A24 and Brightstar TV adaptation soon. On London, the story is murkier. London Falling begins on November 29, 2019, when nineteen-year-old Zac Brettler falls to his death from a luxury apartment above the Thames. Every parent's ultimate nightmare. As it happens, I've known Zac's dad, Matthew, for many years. But what appeared to be a tragic accident or a suicide turned out to be something far more sinister — a story of double lives, dirty money, a dishonest businessman named Akbar Shamji, and a terrifyingly violent gangster known as Indian Dave. Lurking behind the Brettler death is what Keefe presents as the greatest deceit of all — London's cruel descent into what he sees as the moneyed miasma of post-Thatcherite neo-liberalism. London is, in Keefe's compelling narrative, the most invisible of cities — where power lies with criminals like Indian Dave, where the police are at best bystanders, and where a teenage fantasist from a comfortable middle-class family can become fatally entangled in a fallen world he barely understood. Five Takeaways •       Zac Brettler: The Double Life That Led to His Death: Zac Brettler was nineteen years old. He fell — or was pushed, or was forced to jump — from a luxury apartment balcony above the Thames on November 29, 2019. He had been living a double life: to London's criminal underworld, he was Zac Ismailov, the son of a Russian oligarch, heir to a great fortune. He had even fabricated bank statements showing a personal account holding $1 million. Under this guise, he became entangled with Akbar Shamji, a slippery businessman, and a man known as Indian Dave, a violent extortionist. Keefe's reporting suggests Zac jumped to escape from one of these men. Scotland Yard's passivity in investigating the case is, in Keefe's word, bizarre. •       London as a Twenty-Four-Hour Laundromat for Dirty Money: Keefe's portrait of London is the book's macro argument: a global city that has been hollowed out by decades of financial deregulation, whose financial sector is stacked with professional facilitators eager to help protect or conceal a dubious fortune, where posh mansions and private nightclubs serve as the visible surface of a hidden economy of criminal money. Zac Brettler was not rich. He was a boy from a comfortably off family who became fixated on the glitzy, mercenary, aspirational culture embodied by foreign billionaires who had bought mansions and football clubs in his city. London, in Keefe's telling, did this to him. •       The Brettlers' Consent: A Long Haul With the Family: Keefe had written 15,000 words for The New Yorker when he knew there was a book. He went to Matthew and Rochelle Brettler and their surviving son Joe and told them: I will only do this with your blessing. They read the finished piece, talked amongst themselves, and came back with a yes. Keefe's method: he is an open book; he invites sources to read his previous work. It took him an LSE graduate who became one of the most trusted journalists in the world to persuade a devastated family to trust him with their son's story. They made the right decision. •       Narrative as Delivery Device: Keefe's Method: Keefe on why he writes the way he writes: everyone has a phone in their pocket making claims on their attention. Narrative — true stories about real people, told with enough seductive propulsive energy — remains the most powerful way to convey information, to make someone who would not otherwise read nonfiction want to keep turning pages. He is looking, always, for inherently dramatic stories. London Falling is that: a whodunit, a parental love story, a portrait of a corrupted city, and a thriller, all in one book. The New York Times described the whole book as one of the best of 2026 so far. •       The Television Adaptation: A24, Brightstar, and the Lessons of Say Nothing: A24 and Brightstar are producing the television adaptation of London Falling. Five production companies had to audition for the Brettlers over Zoom. The family is involved. Keefe knows from Say Nothing — which took five years from book to screen and won awards as an FX series — that this cannot go on autopilot. The aim: something sophisticated, sensitive, and just to the family's story. The first word on the Mill Hill School website is “integrity.” Whether that word will survive contact with a television adaptation remains to be seen. About the Guest Patrick Radden Keefe is a staff writer at The New Yorker and the author of London Falling: A Mysterious Death in a Gilded City and a Family's Search for Truth (Doubleday, April 7, 2026; #1 New York Times bestseller), Empire of Pain: The Secret History of the Sackler Dynasty (winner of the Baillie Gifford Prize), Say Nothing: A True Story of Murder and Memory in Northern Ireland (National Book Critics Circle Award; named one of the twenty best books of the 21st century by the New York Times), Rogues, and Chatter. He is the recipient of a Guggenheim Fellowship, the National Magazine Award, and the Orwell Prize. He served as executive producer on the award-winning FX series Say Nothing and is the creator and host of the podcast Wind of Change. References: •       London Falling: A Mysterious Death in a Gilded City and a Family's Search for Truth by Patrick Radden Keefe (Doubleday, April 7, 2026). •       Empire of Pain: The Secret History of the Sackler Dynasty by Patrick Radden Keefe — referenced at the opening. •       Say Nothing (FX series, executive produced by Keefe) — referenced in the closing section. •       Andrew O'Hagan, Caledonian Road — referenced as covering similar London territory in fiction. •       A24 and Brightstar — the production companies making the London Falling television adaptatio...

On this episode of The Federalist Radio Hour, Dr. Mary Talley Bowden, a Houston-based ear, nose, throat, and sleep medicine specialist, joins Federalist Elections Correspondent Matt Kittle to discuss her ongoing fight against the healthcare complex, its campaign to push a dangerous Covid-19 shot over other effective treatments, and the widespread effort to silence dissenting voices. You can buy Dr. Bowden's new book, Dangerous Misinformation: The Virus, the Treatments, and the Lies here.The Federalist Foundation is a nonprofit, and we depend entirely on our listeners and readers — not corporations. If you value fearless, independent journalism, please consider a tax-deductible gift today at TheFederalist.com/donate. Your support keeps us going.